Dr. Charles Samuel Kuzma, MD

Dr. Kuzma practices at FirstHealth Moore Regional Hospital in Pinehurst, North Carolina, part of FirstHealth of the Carolinas.

Dr. Kuzma's NPI, 1063469856, was assigned on May 28, 2006. Dr. Kuzma graduated from Temple University School of Medicine in 1992. Dr. Kuzma holds North Carolina license 2009-00759.

Dr. Kuzma's primary practice is FirstHealth Moore Regional Hospital, at 155 Memorial Drive, Pinehurst, NC 28374 in Moore County. The practice phone is (910) 715-1000.

Dr. Kuzma's primary practice is FirstHealth Moore Regional Hospital in Pinehurst, North Carolina, part of FirstHealth of the Carolinas. Dr. Kuzma is also affiliated with UNC Hospitals. The medical group on file is FirstHealth Montgomery Memorial Hospital. Dmand AI also links Dr. Kuzma to 1 more group practice or clinic, 1 hospice and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kuzma practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Kuzma's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Kuzma's licenses on file in 2 states: North Carolina and California.

CMS data shows 633 Medicare services from Dr. Kuzma across 4 procedure codes in 2024, for 301 Medicare patients. Medicare paid $53,488 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 301 Medicare patients who saw Dr. Kuzma in 2024. The largest group is 75 to 84, with 127 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 2.13, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kuzma's median patient age at 75, with 60% women.

In 2024, Dr. Kuzma wrote 1,537 Medicare Part D claims for 251 patients. 75% of them were for generic drugs. CMS names the drug for 1,281 of them, across 37 drugs with 11 or more claims each, at $4,574,348 in total drug cost. In 2023, CMS named 921 claims across 29 drugs.

Dr. Kuzma accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 11 papers to Dr. Kuzma, published from 2014 to 2023. 2021 was the busiest year, with 2. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Adenine and Atrial Fibrillation. Dr. Kuzma has published most often in J Clin Oncol. Dr. Kuzma's most frequent co-authors are Danielle M. Brander, MD, John C. Byrd, MD and Wei Ding, MD.

Dmand AI links Dr. Kuzma to 10 clinical trials, 5 of them phase 3 studies. 10 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Adenocarcinoma, Bronchiolo-Alveolar. National Cancer Institute (NCI) sponsors the most, 10.

CMS Open Payments shows 585 general payments to Dr. Kuzma from 57 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 61% of the total. AstraZeneca Pharmaceuticals LP paid the most, $16,120. It also lists 22 research payments totaling $2,598 in 2019.

Dr. Kuzma graduated from Temple University School of Medicine in 1992.